AstraZeneca Finds Two More Potential Partners For Imfinzi

AstraZeneca PLC appears to have found two novel immuno-oncology partners that can improve outcomes when combined with its PD-L1 checkpoint inhibitor Imfinzi (durvalumab) without adding very much to toxicity, according to early data presented at the European Society for Medical Oncology meeting. It’s a positive step for a company that has contended with several setbacks in establishing Imfinzi in combination regimens, and AstraZeneca could see an even greater victory from a Phase III trial combining Imfinzi with chemoradiation therapy expected to read out later this year

In the Phase II COAST trial presented at ESMO on 17 September, Imfinzi combined with either the CD73-targeting oleclumab or the NKG2A-targeting monalizumab, both monoclonal antibodies in Stage III non-small...